Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
34.82 USD | +2.79% | +2.67% | +57.39% |
01:19pm | Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target | MT |
Apr. 19 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.39% | 1.36B | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+5.27% | 22.25B | |
-14.77% | 21.68B | |
-8.79% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Wells Fargo Adjusts Price Target on Aeglea BioTherapeutics to $0.50 From $0.35, Maintains Equal-Weight Rating